{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:13:16Z","timestamp":1774516396873,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jacc.2021.03.298","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T16:08:29Z","timestamp":1620662909000},"page":"2366-2377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Diabetes-Related Factors and the Effects\u00a0of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials"],"prefix":"10.1016","volume":"77","author":[{"given":"Lawrence A.","family":"Leiter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwee","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tabassome","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamir R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli I.","family":"Lev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00f3bert G.","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Dalby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Ridderstr\u00e5le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Himmelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Prats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Amerena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.03.298_bib1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 Years from the Reduction of Atherothrombosis for Continued Health (REACH) registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.03.298_bib2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus\u2014mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.03.298_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.amjcard.2009.10.048","article-title":"Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the Reduction of Atherothrombosis for Continued Health [REACH] registry)","volume":"105","author":"Krempf","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.03.298_bib5","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990\u20132010","volume":"370","author":"Gregg","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib7","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.03.298_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jdiacomp.2011.10.003","article-title":"The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial","volume":"25","author":"Duckworth","year":"2011","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.jacc.2021.03.298_bib13","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00125-014-3369-7","article-title":"Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes","volume":"57","author":"Zoungas","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2021.03.298_bib14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/dom.14011","article-title":"Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analysis from the DECLARE-TIMI 58 trial","volume":"22","author":"Bajaj","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2021.03.298_bib15","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2021.03.298_bib16","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.03.298_bib17","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.03.298_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/clc.23164","article-title":"Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients intervention study","volume":"42","author":"Bhatt","year":"2019","journal-title":"Clin Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2021.03.298_bib21","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/j.jcjd.2017.10.024","article-title":"Cardiovascular protection in people with diabetes","volume":"42","author":"Stone","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jacc.2021.03.298_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcjd.2018.12.004","article-title":"Erratum to \u201cCardiovascular protection in people with diabetes\u201d: Can J Diabetes 2018;42(S1):S162\u2013S169","volume":"43","author":"Stone","year":"2019","journal-title":"Can J Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2021.03.298_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology\u2014clinical practice guidelines for developing a diabetes mellitus comprehensive care plan\u20142015","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacc.2021.03.298_bib24","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline","volume":"104","author":"LeRoith","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2021.03.298_bib25","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib26","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.03.298_bib27","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.03.298_bib28","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1093\/eurheartj\/ehz707","article-title":"THEMIS and THEMIS-PCI","volume":"40","author":"Bhatt","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.03.298_bib29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1161\/CIRCULATIONAHA.116.023743","article-title":"Clopidogrel versus ticagrelor for antiplatelet maintenance in diabetic patients treated with percutaneous coronary intervention: results of the CLOTILDIA study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients)","volume":"134","author":"Mangiacapra","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.03.298_bib30","article-title":"Impact of diabetes mellitus on the pharmacodynamic effects of ticagrelor versus clopidogrel in troponin-negative acute coronary syndrome patients undergoing ad hoc percutaneous coronary intervention","volume":"6","author":"Sweeny","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.03.298_bib31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.03.298_bib32","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","author":"Ferreiro","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.03.298_bib33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2021.03.298_bib34","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","article-title":"Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized Dual Antiplatelet Therapy Study","volume":"133","author":"Meredith","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.03.298_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005795","article-title":"Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease: a patient-level meta-analysis","volume":"11","author":"Elmariah","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2021.03.298_bib36","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events With ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.03.298_bib37","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMp0806848","article-title":"Prasugrel in clinical practice","volume":"361","author":"Bhatt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.03.298_bib38","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.046448","article-title":"Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.03.298_bib39","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721010226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721010226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:42:14Z","timestamp":1760017334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721010226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0735109721010226"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.03.298","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes-Related Factors and the Effects\u00a0of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.03.298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}